Morgan Stanley analyst Toni Kaplan maintains Equifax (NYSE:EFX) with a Overweight and lowers the price target from $227 to $226.
Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the second patient (EA2) with non-active secondary progressive multiple sclerosis (SPMS) receiving…